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To determine whether veterinarians in primary care practices (PCPs) and board-certified cli-
nicians (BCCs) approach treatment of dogs with immune-mediated haemolytic anaemia
(IMHA) similarly, and whether practitioners with more experience treat similarly to those with
less experience. We hypothesised those in PCPs would show more variation in their
approach to similar cases than BCCs.
Methods
A cross-sectional study was conducted by distributing a questionnaire to BCCs and veteri-
narians in PCPs. The questionnaire included direct questions and a number of clinical sce-
narios intended to capture approaches to common treatment problems.
Results
Questionnaire responses were received from 241 veterinarians, including 216 in PCPs and
25 BCCs. Veterinarians in both settings used similar tests for diagnosis of IMHA, but BCCs
performed more tests to exclude underlying causes of ‘associative’ disease. All veterinari-
ans reported use of similar initial dosages of glucocorticoids (median 2 mg/kg per day in
both groups, p = 0.92) but those used by more experienced practitioners were higher than
those with less experience. Most veterinarians made allowances for the weight of dogs,
using lower prednisolone dosages in a clinical scenario involving a 40 kg dog compared to a
9 kg dog (p = 0.025 for PCP, p = 0.002 for BCC). BCCs reported greater use of combinations
of immunosuppressive drugs (p<0.0001) and of antithrombotic drugs (p<0.0001); use of
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antithrombotic drugs was also less common among more experienced practitioners com-
pared to less experienced.
Conclusions
Approaches to treatment of dogs with IMHA differ between BCCs and those in PCP. These
differences may affect design and implementation of future research studies and clinical
guidelines.
Introduction
Immune-mediated haemolytic anaemia (IMHA) is treated commonly in veterinary referral
hospitals employing board-certified clinicians (BCCs) [1]. However, most dogs with clinical
signs of IMHA are presented initially to a primary care practice (PCP), and many will receive
all of their diagnostic investigations and treatment in this setting if referral is unnecessary,
unaffordable, or unwanted.
Investigation and management of dogs with IMHA in different locations has the potential
to cause important consequences. First, data underpinning all published research studies are
derived from referral hospitals, with no information to indicate whether results are representa-
tive of, or conclusions applicable to, dogs with IMHA that are never referred. Second, BCCs
often lead development of clinical guidelines intended to provide standardised and evidence-
based recommendations for investigation and treatment, including the recent American Col-
lege of Veterinary Internal Medicine (ACVIM) consensus statements on this topic [2,3]. How-
ever, implementation of such guidelines may not be feasible in PCPs, particularly if intensive
forms of investigation and treatment are recommended in all cases. Thirdly, because most
BCCs pass through comparable programmes of specialisation, referral hospitals are likely to
achieve a high level of consistency in their approach to clinical cases, even if unintentionally.
In PCPs, even though all veterinarians historically have trained in specialist veterinary school
hospitals under the supervisions of BCCs, we suspect investigation and treatment of the same
disease could be more varied, dependent on the experience and interests of attending veteri-
narians. Finally, the areas identified by veterinarians as deserving of further investigation dif-
fer, with a large proportion of specialists desiring clinical studies on thromboprophylaxis in
IMHA [4], whereas, in our experience, veterinarians in PCP more often consider the merits of
long-term immunosuppressive treatment and risks of vaccination.
Two recent ACVIM consensus statements have provided recommendations for diagnosis
and treatment of IMHA in dogs, providing a classification system for confidence of diagnosis
as ‘diagnostic’, ‘supportive’, or ‘suspicious’ according to the number of features of immune-
mediated red blood cell destruction and haemolysis that are detectable in each case.
Building on these observations, assumptions, and new resources, the objective of our work
was to gain information on current approaches to investigation and treatment of IMHA out-
side referral hospitals, hypothesising that approaches would be more varied in PCPs compared
to referral practices and would differ with the experience of veterinarians. To achieve this, we
designed a questionnaire that was distributed among veterinarians in primary and specialist
practices in the United Kingdom (UK), incorporating a number of clinical scenarios intended
to capture differences in clinical approach. Importantly, this work was not intended to be jud-
gemental of veterinarians working in PCPs but to generate data to inform future research and
clinical governance projects of the differences in management of IMHA in different settings.
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Materials and methods
Study design
A cross-sectional study was conducted by distributing a single-source written questionnaire to
veterinarians in PCP and to BCCs in the UK between January 2016 and October 2017. All par-
ticipants gave written informed consent for participation in the study, and the questionnaire
and study protocol were approved by the Clinical Research Ethical Review Board of the Royal
Veterinary College (reference number: URN2015_1389).
Questionnaire
We designed the questionnaire to capture information on topics relating to the diagnosis and
treatment of IMHA in PCP and referral practices based on our experience of treating this dis-
ease and interacting with owners and other veterinarians. In addition, we designed a number
of simple clinical scenarios that reflected common problems or differences in opinion that we
have encountered. Veterinarians with recent experience of PCP in our institutions were asked
to complete the questionnaire and provide feedback, which was used to modify several ques-
tions before a final version was created using online software (SurveyMonkey, www.
surveymonkey.com), in which participants could navigate forwards and backwards through
the survey. Ethical approval for distribution of the questionnaire was granted by an institu-
tional ethical review board (URN2015_1389). A transcript of the questionnaire is available in
S1 File.
Distribution to PCPs
A link to the questionnaire was sent in an e-mail to 1,637 veterinarians and 180 practices who
were members of a mailing list previously maintained by a university referral hospital (Royal
Veterinary College) in January 2016. In addition, we obtained publicly-available e-mail
addresses for PCPs from a national database (register of the Royal College of Veterinary Sur-
geons, findavet.rcvs.org.uk), from which we randomly selected 549 practices in 3 different geo-
graphical regions and sent an e-mail with an explanation of the study and the link to the
questionnaire. Owing to the manner in which the questionnaire was distributed, it was not
possible to calculate a definite response rate, but 2,366 separate e-mails were sent to individuals
or practices during the course of the study, of which 160 were undeliverable. Distribution of
the questionnaire was completed before the implementation of Regulation (EU) 2016/679
(General Data Protection Regulation) [5] that would not permit these activities today.
Distribution to BCCs
The names of all American or European board-certified specialists in internal medicine and
emergency and critical care practicing in the United Kingdom (UK) were obtained from cen-
tral databases (VetSpecialists, www.vetspecialists.com; ECVIM listings, www.ecvim-ca.org/
specialist-listings). An e-mail was sent to each of these individuals in August 2017, or to their
practice if a personal e-mail address was not found, providing an explanation of the study and
a link to the questionnaire. In total, e-mails were sent to 69 internal medicine specialists and 8
emergency and critical care specialists.
Data analysis
Questionnaire responses were copied into spreadsheet software (Excel 2016, Microsoft) and
coded for further analysis. Responses from countries other than the UK, which were not solic-
ited, were excluded because availability of tests and drugs and structure of educational
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programmes differ among countries. Responses from individuals who were not board-certified
but working in referral practices were also excluded because their professional role was
unknown. Responses were not excluded if some sections were incomplete; the denominator
for analysis is provided in relevant sections to indicate how many individuals responded to
each question.
In several clinical scenarios, we asked respondents to state the total dose of a drug they
would choose to administer. To compare responses, we divided this answer by the stated
weight of the dog to derive the dosage. Where we asked respondents to state a new dose of a
drug during a dose reduction, we calculated the percentage reduction in dosage from the stated
previous dosage.
Statistical analysis was completed using commercially available software packages (SPSS
version 22, IBM Corp; Graphpad Prism version 7, Graphpad Software Inc). For continuous
variables, distribution was assessed by visual assessment of histograms and using Shapiro-
Wilks tests. Because no variables were normally distributed, results were presented as median
with inter-quartile range, and groups were compared using Mann-Whitney U tests for inde-
pendent samples and Wilcoxon Signed rank tests for paired samples. Categorical variables
were compared between groups using Chi squared or Fisher’s exact tests, according to the
number of cases per cell. The complete dataset is available in S2 File.
Results
Demographic characteristics
Questionnaire responses were received from 261 veterinarians, of which 14 were excluded
because they were based in a different country. Among the remaining 247 respondents, 187
(75.7%) graduated in the UK, 39 (15.7%) in other European countries, 11 (4.5%) in Austral-
asia, 2 (0.8%) in North America, 1 (0.4%) in Asia, 1 (0.4%) in Africa, with 6 (2.4%) choosing
not to provide this information. Among these respondents, 24 were board-certified specialists
in internal medicine working in university (n = 8) or private (n = 16) referral practices and
one was a board-certified specialist in emergency and critical care working at a private referral
practice. Collectively, responses were received from BCCs at 21 different institutions
(Table 1). There were 6 individuals who were not board-certified but worked in a referral
practice; their responses were excluded from further analysis. The remaining 216 respondents
worked in PCPs that treated small animals exclusively (n = 170), or a mixture of small and
large animals (n = 46). The majority of respondents graduated between 2000 and 2015 regard-
less of work setting, with distribution shown in Fig 1. The majority (158/200, 79.0%) of those
in PCP and all BCCs had diagnosed at least one dog with IMHA in the previous year, and
those in PCP estimated that a median of 90% (inter-quartile range [IQR]: 75–100) of cases
were treated in their practice exclusively without referral.
Diagnosis of IMHA
When asked which investigations they undertook to reach a diagnosis of IMHA, BCCs and
those in PCP commonly performed tests to characterise anaemia, albeit more often in-house
at PCPs (complete blood count [CBC] at reference lab, p = 0.391, CBC in-house p<0.0001,
blood smear examination in-house, p = 0.379). Respondents from both groups also performed
tests at similar rates to establish whether there is concurrent hyperbilirubinaemia suggestive of
haemolysis (serum biochemistry, p = 0.395) and to determine whether there are features of
immune-mediated red blood cell (RBC) damage (blood smear examination, saline agglutina-
tion, p = 0.436, and Coombs’ test, p = 0.165) (Fig 2A). To establish whether clinicians were
approaching the diagnosis of IMHA in a similar manner to that recommended in the recent
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ACVIM consensus statement on the same topic [3], we determined whether each respondent
always chose to perform sufficient tests for the ‘diagnostic’ category (two tests for potential
immune-mediated RBC destruction and one test for haemolysis), for the ‘supportive/suspi-
cious’ category (one test for potential RBC destruction and one test for haemolysis), or whether
a test for haemolysis was not always performed, which would preclude a complete diagnosis of
IMHA. Doing so, we found most respondents in both groups always performed sufficient tests
for the ‘diagnostic’ category, reconciling with the similar patterns of use of individual tests (Fig
2B). However, when asking which tests were undertaken to establish if IMHA was associated
with an underlying cause, we found BCCs were much more likely to perform additional tests,
particularly thoracic and abdominal imaging (both p<0.0001) and urinalysis (p = 0.013). Simi-
larly, although BCCs and those in PCPs performed tests for vectorborne infectious agents at
similar rates in those dogs that had travelled outside the UK, BCCs were also more likely to do
so in dogs that did not have a history of travel to another country (p<0.0001 for overall com-
parison, Fig 3). Collectively, this suggests BCCs are more concerned about possible underlying
causes of IMHA than those in PCPs.
Transfusion therapy
The majority of those in both PCPs and specialist practices administered blood transfusions at
their own centre (Fig 4A), but the source of blood products varied, with most referral practices
relying on a national charitable blood bank whereas those in PCPs were more likely to use
local donor animals (Fig 4B). Almost all BCCs obtained the blood type of donor and recipient
before transfusion, but approximately one third of respondents in PCPs did not type either
dog (Fig 4C, p = 0.001 for comparison between groups). Similarly, those in PCPs reported that
dogs needing repeated transfusion were less likely to be cross-matched to donor blood before
transfusion compared to respondents in specialist practices (Fig 4C, p = 0.009).
Immunomodulatory treatment
Following diagnosis, we asked respondents to state the initial dosage of prednisolone they
would administer for treatment of IMHA. An immunosuppressive dosage was selected in all
cases, with a clear preference for a dosage of 2.0 mg/kg (median and inter-quartile range values
all 2.0 mg/kg) among both BCCs and those working in PCP. There was no difference in dosage
Table 1. Demographic characteristics of questionnaire respondents.
Parameter Primary care practice Board-certified clinicians
N 216 25
Gender 170 female (78.7%), 46 male
(21.3%)
18 female (72.0%), 7 male
(28.0%)
Practice type
Small animal only 170
Mixed small and large
animal
46
University referral hospital 3� 8
Private referral hospital 3� 17
Practice size (full time equivalent veterinary positions, median and
IQR)
5.2 (3.0–7.0) 25.0 (18.0–42.0)
IQR: Inter-quartile range.
� Excluded from analysis.
https://doi.org/10.1371/journal.pone.0257700.t001
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between BCCs and those in PCPs (p = 0.905; Fig 5A), but the variability in selected dosage was
greater in the latter group. Among those in PCP, there was a tendency for those graduating
later to use lower initial dosages of prednisolone (Fig 5B).
Because this question represented a simple exercise in recalling an appropriate dosage for
treatment of an immune-mediated disease, we explored the topic further by presenting two
clinical scenarios, both describing recent diagnosis of IMHA: one in a Dachshund weighing 9
kg and the other in a Rottweiler of 40 kg. In these scenarios, respondents were asked to indi-
cate the total dose of prednisolone they would administer (in mg) and its frequency; we calcu-
lated the dosage in our analysis. Although the range of selected dosages was similar to before,
comparison of paired responses from the same individuals showed both BCCs (p = 0.002) and
those in PCP (p = 0.025) chose significantly lower dosages for the 40 kg dog compared to the 9
kg dog (Fig 5C). However, this finding was complicated by the variability of individual
responses in both groups (Fig 5D). In both scenarios, more BCCs and veterinarians in PCPs
Fig 1. Most respondents graduated after 2000. Histograms showing frequencies of year of graduation for (A)
veterinarians in primary care practice (PCP), n = 209 and (B) board-certified clinicians (BCC), n = 25. Bins represent 2
year periods (A) or 5 year periods (B).
https://doi.org/10.1371/journal.pone.0257700.g001
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Fig 2. Respondents in primary care and referral practice have a similar approach to diagnosis of IMHA. (A)
Graphs showing percentage of either board-certified clinicians (BCC, n = 24) or respondents in primary care practice
(PCP, n = 193) that reported use of the named tests for diagnosis of IMHA, Chi-squared or Fisher’s exact tests. CBC:
complete blood count. (B) Graph showing proportion of respondents in each group that always performed sufficient
tests for different categories of diagnostic confidence for IMHA as outlined in the ACVIM consensus statement [3].
https://doi.org/10.1371/journal.pone.0257700.g002
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opted to administer prednisolone twice daily compared to once daily. This decision was largely
consistent across both questionnaire scenarios, though 11/54 (20.4%) of those in PCPs who
chose to administer prednisolone once daily to the 9 kg dog decided to prescribe it twice daily
to the 40 kg dog, suggesting veterinarians may prefer fractionated doses if the total daily dose
is larger (Fig 6).
Use of additional immunosuppressive drugs alongside glucocorticoids has become a con-
troversial topic in the treatment of IMHA [6]. Of a total of 180 responses on this subject, 94
veterinarians in PCP (59.5%) stated they used a combination of immunosuppressive drugs,
compared to all 22 BCCs (100%, p<0.0001). Principal reasons for using combination therapy
were similar in PCPs and BCCs (p = 0.409), with the most frequent reason in PCP (35/89,
39.3%) being a belief this would achieve faster or more effective control of disease, whereas
Fig 3. Board-certified clinicians reported more frequent use of additional tests to exclude underlying causes of
IMHA. Graphs showing percentage of either board-certified clinicians (BCC, n = 24) or respondents in primary care
practice (PCP, n = 193) that reported use of the named tests for diagnosis of IMHA. Chi-squared or Fisher’s exact tests.
https://doi.org/10.1371/journal.pone.0257700.g003
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board-certified specialists most commonly used a combination to alleviate the adverse effects
associated with glucocorticoids (8/20, 40.0%; Fig 7). In both groups, a similar proportion (55/
91, 60.4% of those in PCP and 10/21, 47.6% of BCC, p = 0.283) indicated they treated with glu-
cocorticoids initially and then introduced another drug later if the response was inadequate.
Of the immunosuppressive drugs used alongside glucocorticoids in dogs with IMHA, use
of cyclophosphamide has been discouraged owing to a possible detrimental effect on outcome
[7]. Whereas azathioprine has been available for decades in veterinary practice, other drugs,
including ciclosporin [8], mycophenolate mofetil (MMF) [9], and leflunomide [10] have only
been used in veterinary clinical practice more recently. This pattern appeared to be reflected in
the responses to our questionnaire, with ciclosporin, MMF, and leflunomide all used more fre-
quently by BCCs (all p<0.0001), whereas azathioprine was used at similar levels in both set-
tings (p = 0.150; Fig 8). Cyclophosphamide was used often or occasionally by 21/159 (13.2%)
of those in PCP and occasionally by 2/22 (9.1%) BCCs, with no significant difference between
groups (p = 0.831).
Respondents estimated that dogs with IMHA require immunosuppressive treatment for a
median of 5.0 months (IQR: 3.5–6.0), with similar values provided by those in PCP (median
5.5 months, IQR: 3.5–6.5) and BCCs (median 5.0 months, IQR: 4.5–6). There was considerable
variation in the narrative descriptions given by respondents on their approach to tapering
drug doses over time and on the frequency of re-examination visits (S2 File). At follow-up
Fig 4. Blood transfusions are widely available in veterinary practice but extent of pre-transfusion testing differs.
(A) Graph showing proportion of respondents in primary care practice (PCP, n = 191) or of board-certified clinicians
(BCC, n = 24) reporting availability of blood transfusions in their practice. (B) Graph showing proportion of PCP and
BCC respondents reporting indicated sources of blood products in their practice. (C) Graphs showing proportion of
PCP and BCC reporting use of blood typing (left) and cross-matching (right) in their practices. Chi-squared or Fisher’s
exact tests.
https://doi.org/10.1371/journal.pone.0257700.g004
PLOS ONE Management of IMHA in veterinary practices
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Fig 5. Respondents in primary care practice reported more varied initial dosages of prednisolone. (A) Graph
showing initial glucocorticoid dosage used by those in primary care practice (PCP, n = 116) or board-certified
clinicians (BCC, n = 22). Points represent individual responses, bars represent median. Inter-quartile range values
were the same as the median in both groups. Groups compared with Mann-Whitney U test. (B) Boxplot showing
initial glucocorticoid dosage selected by those in PCP according to year of graduation, annotated with number of
respondents per group. Boxes show median with 25th and 75th percentiles, whiskers show minimum and maximum
values. (C) Graphs showing dosage selected by those in PCP, n = 133 and BCCs, n = 21 in two clinical scenarios
concerning initial dosage of glucocorticoids in a dog recently diagnosed with IMHA. Points represent median with
inter-quartile range. Dotted lines indicate median value provided in Fig 5A to show difference from answers to that
question. Responses compared with Wilcoxon signed rank tests. (D) Individual paired responses for those in PCP and
BCCs for the two clinical scenarios. Individuals selecting the same dosage are marked with a black line, those using a
higher dosage in the heavier dog are marked with a red line, and those using a lower dosage in the heavier dog are
marked with a blue line.
https://doi.org/10.1371/journal.pone.0257700.g005
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visits, BCCs and those in PCPs undertook packed cell volume measurement or CBCs, serum
biochemical profiles, urinalysis by free catch, and blood pressure measurements with similar
frequency (p = 0.217, p = 0.237, p = 0.201, and p = 0.057 respectively), but BCCs were more
likely to obtain urine samples for culture by cystocentesis (p<0.0001) (Fig 9).
Antithrombotic treatment
Immune-mediated haemolytic anaemia is associated with hypercoagulability [11] and an
increased risk of thromboembolic disease [12], and thromboembolism is observed in a high
proportion of dogs that die early in the course of disease [12]. Recent guidelines for treatment
of IMHA recommend strongly that all dogs receive thromboprophylaxis alongside immuno-
suppressive treatment unless severely thrombocytopaenic [2,13]. However, among 181 indi-
viduals responding, only 93 (51.4%) indicated they ever used any antithrombotic drugs in
dogs with IMHA. The frequency of this treatment differed according to setting, with 71/159
(44.7%) of those in PCP administering thromboprophylaxis at least occasionally, compared to
22/22 (100%) of BCCs (p<0.0001). This difference was apparent for prescribing of all forms of
antithrombotic drug except for unfractionated heparins, which were rarely used by respon-
dents from either group (Fig 10A). In addition to those drugs shown in Fig 10A, one BCC
Fig 6. Clinicians administer glucocorticoids once daily or twice daily with similar frequency in clinical scenarios.
Alluvial plots showing intended frequency of administration (f) of prednisolone by board-certified clinicians (BCC)
(bottom) and those in primary care practices (PCP) (top) in two clinical scenarios when asked to indicate their
preferred starting dose of prednisolone for treatment of 2 dogs of different weights, indicated by ‘9 kg’ and ‘40 kg’ over
the corresponding nodes. Respondents indicated they administered prednisolone either once daily (‘1’) or twice daily
(‘2’) in these clinical scenarios, with some respondents making a different choice between the 2 scenarios.
https://doi.org/10.1371/journal.pone.0257700.g006
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indicated that they occasionally used the oral factor Xa inhibitor rivaroxaban. Among those in
PCP, the proportion of respondents administering antithrombotic medications increased with
more recent graduation (Fig 10B).
Vaccination in dogs with previous IMHA
In our practices, we are asked frequently by owners whether their dog with IMHA can be vacci-
nated, either while still receiving treatment or after maintaining complete remission for long peri-
ods of time. A previous study suggested recent vaccination could be a risk factor for the first
occurrence of IMHA [14] and, though contradicted by a later study [15], we believe the notion
that vaccination will cause relapse is widespread among veterinarians. To explore this idea, we
presented a clinical scenario describing a dog in complete remission with no treatment for 6
months that is due to be vaccinated. Presented with this situation, 94 of 164 respondents (57.3%)
opted to vaccinate, whereas 70 (42.7%) refused, reflecting a clear division in opinion. This decision
was not significantly different between work settings (with 85/143, 59.4% of those in PCP and 9/
21, 42.9% of BCC, p = 0.164, choosing to vaccinate). Some respondents (n = 20) indicated they
would offer measurement of antibody titres, whereas others expressed a strong view that vaccina-
tions are associated with relapse of IMHA (n = 18) or indicated they would treat the dog with glu-
cocorticoids before and after vaccination to alleviate any risk of relapse (n = 2).
Discussion
In this study, we show there are similarities and important differences in the clinical approach to
treatment of IMHA in dogs in PCPs and referral hospitals. Whereas veterinarians in both settings
Fig 7. Primary care practitioners and board-certified clinicians use a combination of immunosuppressive drugs
for different reasons in the clinic. Bar graph showing the percentage of respondents who administered a combination
of drugs principally for the indicated reasons, separated according to group. PCP: primary care practitioner, n = 89.
BCC: board-certified clinician, n = 20. CE: continuing education. Groups compared with Chi squared test.
https://doi.org/10.1371/journal.pone.0257700.g007
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performed diagnostic tests needed to confirm a diagnosis of IMHA with similar frequency, BCCs
were much more likely to undertake extensive investigations for possible underlying causes of
immune-mediated disease. Respondents in both groups reported use of glucocorticoids at similar
dosages and with similar adjustments for bodyweight, and, although both groups used combina-
tion immunosuppressive treatment at similar rates when commencing therapy, BCCs reported
always using a combination of drugs rather than glucocorticoids alone in cases they treated. Fur-
thermore, reported use of antithrombotic treatment was limited in PCPs, particularly among
practitioners that graduated earlier, but was used more extensively by BCCs.
Fig 8. Primary care practitioners and board-certified clinicians use different combinations of immunosuppressive
drugs in the clinic. Bar graphs showing the percentage of respondents using (A) azathioprine, (B) ciclosporin, (C)
mycophenolate mofetil, MMF, (D) cyclophosphamide, or (E) leflunomide with indicated frequency according to
group. PCP: primary care practitioner, n = 159. BCC: board-certified clinician, n = 22. Chi-squared or Fisher’s exact
tests.
https://doi.org/10.1371/journal.pone.0257700.g008
PLOS ONE Management of IMHA in veterinary practices
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Others have speculated that dogs with IMHA treated at referral hospitals represent a subset
with more severe disease [16]. If true, this could confound our observations because BCCs and
those in PCP could be investigating and treating different subtypes of IMHA, resulting in differ-
ences in clinical approach. While our study suffers from a lack of objective data to determine
whether cases treated in these different settings were similar at diagnosis, we suspect there is
considerable overlap between these groups because those in PCPs reported 90% of dogs were
being treated exclusively in that setting, with more than 25% not referring any dogs with
IMHA. If cases seen by BCCs were more severely affected, we would also expect intensity of
treatment to be greater in that group, whereas, if anything, the opposite appeared to be true. For
example, BCCs rarely used a starting dosage of prednisolone above 2 mg/kg per day and most
Fig 9. Board-certified clinicians obtain more urine samples by cystocentesis during follow-up visits. Bar graphs
showing percentage of respondents performing indicated tests at indicated frequencies according to group during
follow-up visits for dogs being treated for IMHA. PCP: primary care practitioner, n = 152. BCC: board-certified
clinician, n = 22. Chi-squared or Fisher’s exact tests.
https://doi.org/10.1371/journal.pone.0257700.g009
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often used another drug to limit glucocorticoid-related adverse effects. Additionally, we did not
ask respondents about situations that would be unique to primary or specialist care, with all sce-
narios and use of all named tests and drugs being feasible in either setting. Therefore, we suggest
that differences observed in this questionnaire may represent genuine differences between set-
tings in the approach to investigation and management of IMHA in dogs, but further objective
data are needed to determine whether disease severity differs in referred dogs.
Fig 10. Antithrombotic treatment is not used by the majority of respondents in primary care practice. (A) Graphs
show the proportion of respondents using aspirin, clopidogrel, low molecular weight (LMW) heparins, or
unfractionated (UF) heparins. PCP: primary care practice, n = 159. BCC: board-certified clinician, n = 22. Groups
compared with Chi squared or Fisher’s exact tests. (B) Proportion of respondents in PCP using any antithrombotic
product at least ‘occasionally’ by year of graduation, annotated with number of respondents per group.
https://doi.org/10.1371/journal.pone.0257700.g010
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Authors of a recent ACVIM consensus statement recommended that various tests, includ-
ing thoracic and abdominal imaging, be undertaken to detect concurrent diseases that might
promote dysregulated immune responses to produce so-called ‘associative’ IMHA [3]. How-
ever, two recent studies indicate that dogs with IMHA fulfilling multiple diagnostic criteria
rarely have abnormalities on thoracic imaging and often do not have findings of clinical signif-
icance on abdominal imaging, suggesting these tests have low diagnostic yields and may be dis-
pensable in many cases [17,18]. Accordingly, we were interested to note that imaging was
performed less commonly by those in PCPs in our study compared to BCCs, which probably
reflects a difference in the perceived cost-benefit balance between these settings. We speculate
that this difference could be attributable to differences in the severity or complexity of cases
referred to specialist centres, to lower concern among those in PCPs for possible underlying
causes of IMHA, or to a culture among BCCs that may set a higher value on ‘completeness’ of
investigations.
Of the vectorborne pathogens suggested to have some association with IMHA in dogs, only
Anaplasma phagocytophilum is endemic in the UK, and the level of evidence linking this path-
ogen with disease is considered to be low [3]. However, autochthonous cases of Babesia canis
[19] and Ehrlichia canis [20] have been reported recently in untravelled dogs, suggesting new
pathogens may become established with changes in climate that permit survival of new tick
species and with increases in international movement of dogs. We were therefore interested to
note that BCCs more often performed testing for vectorborne agents in dogs that did not have
a history of travel outside the UK, suggesting BCCs may be more aware of or concerned about
emerging infectious diseases than those in PCPs.
Individuals pursuing specialist training participate in standardised programmes that
require candidates to be familiar with recent scientific literature. We believe this may explain
the remarkable consistency in responses from BCCs, with most appearing to undertake similar
diagnostic investigations, treat cases similarly after diagnosis, and make similar decisions in
clinical scenarios. In PCPs, exposure to these materials may be more limited, possibly explain-
ing the greater variability in some parameters, such as the starting dosage of prednisolone.
These factors could also explain the difference in use of antithrombotic treatment between set-
tings, even though, in our experience, drugs such as aspirin or clopidogrel are stocked by most
PCPs. We were interested to note the increasing use of antithrombotics in those graduating
after 2000 because the first major study to describe use of aspirin for dogs with IMHA was
published in 2005 [21], meaning those graduating earlier may not be familiar with its contents
from their university education.
We found approaches to pre-transfusion testing varied considerably, with some clinicians
choosing not to perform blood typing of donor or recipient before transfusion. This could be
attributable to limited availability of blood typing kits in some practices or could be a con-
scious choice because transfusion reactions have not been described for transfusion naïve dogs
receiving their first DEA1 mismatched transfusion. However, because dogs with IMHA may
require multiple transfusions, others have recommended that blood typing before transfusion
can be used to prevent sensitisation of DEA1 negative recipients to DEA1 positive blood,
avoiding the risk of severe haemolytic reactions if a sensitised dogs receives a mismatched
transfusion [22]. Similarly, some clinicians indicated they would not perform crossmatching
in dogs requiring a subsequent transfusion, which is likely to increase the risk of haemolytic
reactions [23].
Glucocorticoids are used widely in veterinary practice, with approximately 25% of non-vac-
cine consultations in PCPs in the UK resulting in their systemic administration [24]. However,
use of glucocorticoids at immunosuppressive dosages produces severe adverse effects, which
may impair quality of life [8,25–27]. For this reason, in the recent ACVIM consensus
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statement on treatment of IMHA, panel members recommended against exceeding an initial
dosage of 3 mg/kg per day, with some indicating they did not see an indication for more than
2 mg/kg per day owing to the presumed risk of severe adverse effects without any additional
clinical benefit [2]. Despite this, some in PCPs reported using dosages as high as 5–8 mg/kg
per day, with practitioners graduating earlier also using greater dosages, whereas those gradu-
ating after 2000 were more likely to use dosages of 1.5 mg/kg per day or less. We suggest this
may reflect a greater concern among those in PCP to control haemolysis, whereas BCCs might
be more concerned by adverse effects, also leading them to use an additional immunosuppres-
sive drug more frequently for this purpose. By highlighting these differences, we do not wish
to pass judgement on veterinarians working in PCPs because there is no published evidence
comparing outcome for dogs with IMHA treated with different dosages of prednisolone.
Instead, we wish to emphasise that individuals in different settings are apparently reaching dif-
ferent conclusions in their cost-benefit analysis on these questions, which probably reflects dif-
ferences in the perceived importance and awareness of different aspects of the disease.
Many BCCs and practitioners in PCPs made allowance for bodyweight when selecting
doses of prednisolone for initial treatment of dogs with IMHA. This is important because met-
abolic rate is more closely related to surface area than bodyweight [28], meaning that lower
total doses are required to achieve the same blood concentrations of prednisolone in larger
dogs [29]. Consequently, dosing according to surface area may be an effective practice to limit
adverse effects in larger dogs, as recommended previously [2].
In corresponding with owners and veterinarians, a topic we encounter frequently concerns
the vaccination of dogs that have recovered completely from IMHA, and our study confirmed
a striking difference of opinion regardless of practice setting. Aside from published evidence,
this debate is also affected by other information, including global anti-vaccine sentiments and
information provided by vaccine manufacturers. Many respondents to our questionnaire indi-
cated they would offer measurement of antibody titres against pathogens composing the major
vaccines, but this approach is not suitable for some pathogens with labile serological responses,
such as Leptospira spp. Uncertainty on this topic warrants further, prospective investigation of
the risk of relapse after vaccination in dogs with IMHA, weighed against the occurrence of
infectious diseases in those not vaccinated. A recent survey-based retrospective study sug-
gested there was no increased risk of reactions in dogs with IMHA receiving vaccines after
diagnosis, but this study may have been underpowered because relapse after finishing treat-
ment occurs in only a small proportion of dogs with IMHA [30].
In a cross-sectional study, it is not possible to determine whether associations are causal
because they could be confounded by unmeasured variables. Therefore, while we might specu-
late that differences between those in PCP and BCCs could be attributable to specialist train-
ing, this cannot be demonstrated without longitudinal data to compare treatment approaches
of the same individuals before and after training. Our study has a number of additional limita-
tions, including a lack of qualitative interviews on the controversial topics identified and a lack
of objective data. Respondents to the questionnaire could have been veterinarians with a par-
ticular interest in this subject or particular enthusiasm for participating in surveys, both of
which could introduce bias in our results. We offered only the option of a computer-based
questionnaire for respondents, when other individuals might have responded if they could
have completed a paper copy. We were concerned that respondents might answer questions
based on theoretical knowledge rather than clinical acumen, leading us to include clinical sce-
narios. However, these provided limited descriptions of clinical situations, with no facility to
request further information, as would be possible in reality. Consequently, responses could
have been biased by our descriptions or the wording of the scenarios and may not reflect accu-
rately the decisions being made by clinicians. Our scenarios and other parts of the
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questionnaire neglected the opinions of owners on the treatment of their dogs, which is an
essential component of clinical decision-making that would affect many of the situations we
described. Although we compare responses to our questionnaire with information provided in
the ACVIM consensus statements, the publication of these statements could have changed
clinical practice since the questionnaire was completed, highlighting the importance of repeat-
ing our survey in future to determine whether guidelines are disseminated effectively. Finally,
while statistical tests used in this study are not affected by unequal group sizes, the difference
in the relative number of veterinarians in PCP and BCCs may have increased the risk of type II
errors. This means further differences between those in PCPs and BCCs could have been
apparent if the group sizes were more equal, and the small number of responses from BCCs in
this study is a clear limitation. Additionally, the lack of responses from those clinicians special-
ising in emergency and critical care deprives this study of an important contribution from a
group of clinicians who also manage dogs with IMHA.
Taken together, the results of our study reveal differences in the treatment of dogs with
IMHA in PCPs and referral practices, which may have important consequences for the design
and applicability of future research. We show treatment decisions may differ with time since
graduation in PCPs, suggesting there may be a trade-off between clinical experience and efforts
to implement recent scientific literature. Finally, our results reveal a striking lack of consis-
tency in treatment intentions for IMHA, highlighting a clear need for effective dissemination
of published clinical evidence through provision of clinical guidelines, checklists, implementa-
tion of the clinical audit cycle, and continuing education.
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